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Primary graft failure (PGF) is a devastating complication that occurs in the immediate postoperative period following heart
transplantation.Itmanifestsassevereventriculardysfunctionofthedonorgraftandcarriessigniﬁcantmortalityandmorbidity.In
the last decade, advances in pharmacological treatment and mechanical circulatory support have improved the outlook for heart
transplant recipients who develop this complication. Despite these advances in treatment, PGF is still the leading cause of death
in the ﬁrst 30 days after transplantation. In today’s climate of signiﬁcant organ shortages and growing waiting lists, transplant
units worldwide have increasingly utilised “marginal donors” to try and bridge the gap between “supply and demand.” One of
the costs of this strategy has been an increased incidence of PGF. As the threat of PGF increases, the challenges of predicting and
preventing its occurrence, as well as the identiﬁcation of more eﬀective treatment modalities, are vital areas of active research and
development.
1.Introduction
Heart transplantation is an eﬀective method of treatment
for end-stage heart failure, with more than 5,000 transplants
beingconductedeachyearinover300countries[1].Thesur-
vival rate after heart transplantation has improved steadily
over the last two decades with virtually all of the improve-
ment being in survival during the ﬁrst few months [1].
Despite this improvement in early post-transplant survival,
there is little if any evidence that deaths due to primary graft
failure (PGF) have decreased over this period. In a large ret-
rospective study of 7,259 heart transplant recipients during
thedecadefrom1990to2000,Youngandcolleaguesreported
that the one month mortality after heart transplantation
was 6.9% with 43% of these deaths due to PGF [2]. This
compares with the most recent audit of the International
Society of Heart and Lung Transplantation Registry which
reported a one month mortality after transplantation of
8% with 39% of these deaths resulting from PGF [1]. It is
clear from these data that PGF continues to be the single
most common cause of death within the ﬁrst month after
heart transplantation [1]. In addition, the high morbidity
associated with PGF and its treatment is likely to be a major
contributor to deaths that are attributed to other causes such
as infection and rejection over subsequent months.
2. Incidence
The reported incidence of PGF after heart transplantation
varieswidelybetweenstudieswithestimatesrangingbetween
2.3 and 26% [3–11]. Most of the variability can be attributed
to inconsistent deﬁnitions of PGF used by diﬀerent authors.
In a large retrospective review of the UNOS Registry, Russo
and colleagues deﬁned PGF as death or retransplantation
within the ﬁrst 90 days of transplantation and reported an
incidence of only 2.5% [5]; however, as argued by others, the
use of such a deﬁnition based on “hard endpoints” is likely
to underestimate the true incidence of the clinical syndrome
as it only detects those with the worst clinical outcomes
[12, 13]. In contrast, when PGF has been deﬁned as the need
for high-dose inotropes or mechanical assist devices in the
immediate post-transplant period, most investigators have
reported incidence rates of 10–20% or higher [3, 4, 7–9].2 Journal of Transplantation
Table 1: Suggested diagnostic criteria for primary graft failure [7, 9].
Presence of Evidenced by
Ventricular systolic dysfunction—left, right, or
biventricular dysfunction Echocardiographic evidence of dysfunction
Cardiogenic shock lasting more than one hour
Low systolic blood pressure < 90 mmHg and/or
low cardiac output—<2L/minute/m2
Despite adequate intracardiac ﬁlling pressures—CVP > 15mmHg
and/or PAWP > 20mmHg
Circulatory support
Use of ≥2 inotropic agents/vasopressors including high-dose
epinephrine or norepinephrine and/or
use of a mechanical assist device—IABP, ECMO, VAD
A p p r o p r i a t et i m ef r a m e O n s e t< 24 hours after transplantation
Exclusion of secondary causes of PGF For example, cardiac tamponade and hyperacute rejection
The changing demographics of donors and recipients
observed in cardiac transplantation over the last two decades
appear to be contributing to an increase in the incidence of
PGF [9, 11, 14]. Transplant centres face signiﬁcant donor
shortages and growing waiting lists. This is no more evident
than in Australia, where the combination of a relatively small
population and low organ donation rate has resulted in
increased utilisation of hearts from older “marginal” donors
[11, 14, 15] and suboptimal organs from younger donors.
In addition to this, greater procurement distances to retrieve
donor hearts in Australia contribute to prolonged ischaemic
times.Thecombinationofthesetwofactors,advanceddonor
age and prolonged ischaemic time, markedly increases the
risk of PGF and death after heart transplantation [5, 16].
3. Deﬁnition andDiagnosticCriteria
PGF is a syndrome in which the transplanted heart fails
to meet the circulatory requirements of the recipient in
the immediate post-transplant period as a consequence of
either single or biventricular dysfunction. It is manifested
as hypotension and low cardiac output in the presence of
adequate ﬁlling pressures [17]. In most instances, it is likely
to result from a multifactorial process with contributing ele-
ments from the donor, recipient, and the transplant process.
A universally accepted clinical deﬁnition for PGF has
been lacking and is urgently needed. Several authors have
suggested minimal diagnostic criteria [7, 9], which are sum-
marised in Table 1. The primary diagnostic criterion for PGF
is evidence of ventricular dysfunction which may involve the
left, right, or both ventricles occurring within the ﬁrst 24
hours of heart transplantation. The major clinical manifes-
tation of this dysfunction is severe haemodynamic instability
with cardiogenic shock. A diagnosis of PGF should only be
made when other causes of acute graft failure such as cardiac
tamponade and hyperacute rejection have been excluded.
The severity of PGF can be graded according to the
level of support needed to restore haemodynamic stability.
In less severe cases, intravenous inotropic support with two
or more agents may be suﬃcient to achieve this, whereas in
more severe cases mechanical circulatory assistance (includ-
ing intra-aortic balloon pump, extracorporeal membrane
oxygenator (ECMO), or any ventricular assist device) is
required. A three-level grading system based on the severity
of primary graft dysfunction has been developed for lung
transplantation and shown to be strongly predictive of one-
month mortality [18, 19]. It seems likely therefore that the
severity of cardiac PGF has an equally signiﬁcant prognostic
value after transplantation. In view of this, a standardised
clinical deﬁnition of PGF incorporating a severity grading
system is urgently needed.
4.Aetiology andPathogenesis
Acute ischaemia-reperfusion injury with myocardial stun-
ning has been postulated as a predominant factor in the
development of PGF. The donor heart is subjected to a series
ofinsultsduringthetransplantprocessincludingbraindeath
and its sequelae, hypothermic storage, warm ischaemia, and
ﬁnally reperfusion. Donor hearts vary in their ability to
withstandtheseinsults.Itisclear,forexample,thatthehearts
from older donors have an increased susceptibility to PGF
[5, 16] which may be explained by the observation that
agedmyocyteshaveareducedabilitytowithstandischaemia-
reperfusion injury [20].
Brain death in the donor is associated with a series
of events that result in impaired myocardial contractility.
These events include the rapid release of catecholamines
immediately after brain death contributing to myocardial
ischaemia, calcium overload, calpain activation, and changes
in the calcium sensitivity of contractile proteins [21, 22]. The
surgeinendogenouscatecholaminereleaseimmediatelyafter
brain death followed by the administration of exogenous
catecholamines during donor resuscitation may contribute
to desensitization of the myocardial beta-receptor signal
transduction system after brain death and to the activation
ofmultipleproinﬂammatorymediators[23–26].Inaddition,
decreased serum levels of various hormones including
triiodothyronine, cortisol (after a transient increase), and
insulin have been reported and likely contribute to the
depression of myocardial contractility [27].
Most donor hearts are stored in a cold preservation
solution and transported on ice. Hypothermic storage
slows but does not completely arrest cellular metabolism.Journal of Transplantation 3
Table 2: Risk factors for primary graft failure.
Donor factors Recipient factors Procedural factors
Age [2, 5, 7, 9, 16, 33]A g e [ 3, 33] Ischaemic time [2, 3, 7, 9, 11, 33]
Cardiac dysfunction on echo [2, 3, 11] Ventilator support [2] Donor recipient weight mismatching [2]
High-dose inotropic support [3, 6, 34] Intravenous inotropic support [9],
Mechanical support [3, 5] Female donor to male recipient [2, 5, 35]
Cause of brain death [3, 36] Pulmonary hypertension [17, 29–31] Concomitant lung retrieval [5]
Primary graft dysfunction of other organs
[8] Overweight [37], Diabetes mellitus [9]
Consequently, progressive ischaemic injury is an inevitable
consequence of prolonged static storage. In addition, loss
of normal aerobic metabolism paralyses the transmembrane
Na+/K+ ATPase pump leading to cellular swelling and
the switch to anaerobic metabolism during cold storage
results in a rapid decline in high-energy phosphates and
the development of lactic acidosis [28]. Finally, reperfusion
injuryresultsinfurthercalciumoverloadandoxidativestress
both of which can contribute to the mechanism of stunning
[21, 28]. Thus, at every stage of the transplant process, the
heartisexposedtocellularstressesthatmayadverselyimpact
on myocardial function and ultimately lead to the syndrome
of PGF.
Primary graft failure may also occur in circumstances
where the donor heart has not been subjected to substantial
ischaemia-reperfusion injury. Under these circumstances,
recipientfactorsaretheprincipalcauseofPGF.Therearetwo
clinical scenarios where this is likely to occur. The ﬁrst is the
presence of a ﬁxed high pulmonary vascular resistance in the
recipient [29–31]. In this circumstance, the right ventricle of
the donor heart is unable to overcome the afterload imposed
by the elevated pulmonary vascular resistance, and selective
or predominant right ventricular failure ensues. In one series
of 911 patients, 28 of 130 deaths were due to acute graft
failure with 43% of this early mortality (12 of 28 patients),
attributed to severe preoperative pulmonary hypertension
causing right-sided circulatory failure, low cardiac output
andeventuallybiventricularfailure[32].Thesecondscenario
is when the recipient is critically ill on ventilatory and/or
acute mechanical circulatory support often with evidence of
multisystem failure and sepsis [2, 3, 5]. In this circumstance,
the“hostileenvironment”oftherecipientresultsinPGF.The
pathophysiology of PGF in this setting is poorly understood
but probably involves the concerted action of multiple
proinﬂammatory cytokines on the transplanted heart.
In most instances, it is likely that the combination of
donor, procedural and recipient factors leads to the syn-
drome of PGF. For example, an older donor heart that has
been subjected to a prolonged ischaemic time may fail in
a recipient with an elevated pulmonary vascular resistance
whereas a younger donor heart may not. On the other hand,
the same older donor heart may function adequately in
a haemodynamically stable recipient with low pulmonary
vascular resistance. Hence, matching donors to recipients
with regard to risk factors for PGF are critical to minimising
the risk of this life-threatening complication.
5. Risk Factors for PGF
Given the signiﬁcant contribution of PGF to early mortality
after cardiac transplantation, identiﬁcation of predictive
factors is important. Multiple risk factors for PGF have been
identiﬁed by diﬀerent authors. They can be divided into
those that are donor related, those that are recipient related
and those related to the transplant procedure.
AsshowninTable 2,multipledonorandrecipientfactors
have been associated with an increased risk of PGF. Principal
among these are increasing donor and recipient age, both
of which have also been identiﬁed as major risk factors for
one-year mortality after transplantation [1]. The review of
the Australian & New Zealand Cardiothoracic Transplant
Registry reveals that there has been a steady rise in mean
donor and recipient age over the last 2 decades [15] with the
mean donor age exceeding 40 years of age for the ﬁrst time in
2010 (personal communication with Mr. Ross Pettersson).
Another potent risk factor for PGF identiﬁed in multiple
studies is donor heart ischaemic time, referring to the period
fromthearrestofthedonorhearttotimeofgraftreperfusion
in the recipient. It is apparent from the ISHLT Registry that
one-year mortality risk after heart transplantation increases
steadily with every minute of ischaemic time in excess of
3h o u r s[ 1]. Marasco et al. estimated that the risk of PGF
increased by 43% for every hour of extra ischaemic time
beyond 4 hours [7]. As with donor age, there has been a
signiﬁcant increase in donor heart ischaemic time for heart
transplants performed in Australia and New Zealand from a
meanof less than 3hours prior to 1990 toa meanin excessof
4 hours for most of the last decade [15]. In our own recently
reported experience of ECMO support for PGF, donor heart
ischaemic times of 5 hours or longer were associated with a
ﬁvefold increase in the risk of PGF [11].
These data indicate that the current techniques used to
preserve the donor heart during procurement and transport
have limited eﬃcacy. Unfortunately, prolonged ischaemic
times in heart transplantation are sometimes logistically
unavoidable. There is a clear need to develop more eﬀective
preservation strategies—either by bolstering the cardiopro-
tective eﬃcacy of the storage solution or through use of
oxygenated ex vivo perfusion systems. Counter-intuitively,
Russo et al. reported an increased risk of PGF with ischaemic
time of less than 1 hour, citing the potential limited cooling
period being insuﬃcient to achieve the beneﬁts of cellular
protection with global hypothermia [5].4 Journal of Transplantation
Several authors have reported that donor heart dysfunc-
tionasevidencedbyalowleftventricularejectionfractionon
echocardiography, unstable donor haemodynamics, or the
need for high doses of catecholamines is a potent risk factor
for PGF [2, 3, 6, 11]. Historically, donor hearts that displayed
these characteristics would have been regarded as unsuitable
for transplantation; however, increased demand for trans-
plantation has led to many Transplant Units including our
own making use of these “marginal” hearts [3, 6, 11, 14].
Theexpectationisthatthemyocardialdysfunctionevidentin
the donor is a result of stunning and is recoverable over time
despite the current lack of a useful clinical measure that can
reliably distinguish reversible from irreversible myocardial
dysfunction in the brain dead donor. Of all the clinical
information available regarding a potential heart donor, a
young donor age (<30 years) and the absence of any known
history of heart disease are probably the two pieces of clinical
information that our group most relies on when deciding to
use a donor heart with overt myocardial dysfunction prior to
procurement [11].
Donor-recipient size mismatch has also been identiﬁed
as a signiﬁcant contributing factor in the development of
PGF. In one study, the combination of a donor-recipient
weight ratio of less than 0.8 with pulmonary hypertension
in the recipient (>4 wood units) was associated with PGF
[5]. Several studies have found that the transplantation of
a female donor heart into a male recipient was associated
with increased PGF, with size mismatch being the likely
connection. A possible link to immunological processes and
increased rejection episodes have also been described [2, 35].
The concurrent donation of other organs may also have
ar o l ei nP G F ,s p e c i ﬁ c a l l yt h ed o n a t i o no fl u n g s[ 5]. The pro-
posed aetiologies include additional ﬂush volume that may
contribute to RV distension and dysfunction, and release
of pulmonary vascular cytokines at time of arrest which
can result in ventricular dysfunction [5]. The association of
PGF in multiple organs retrieved from the same multi-organ
donor has also been reported, highlighting the potential for
signiﬁcant donor inﬂuences in the development of PGF [8].
This also allows predictability of PGF through monitoring of
other organs transplanted from that speciﬁc donor [8].
The presence of ventilator or ECMO support in the
recipient prior to and at the time of transplantation has been
shown to be a signiﬁcant risk factor for PGF [2, 5]. These
patients are usually critically ill with evidence of multi-organ
dysfunction and often sepsis. Conversion of these patients
to long-term mechanical support with a left ventricular
assist device or total artiﬁcial heart is associated with
signiﬁcant mortality [38], but if successfulenables resolution
ofanyacutemulti-organdysfunctionwithsubsequentlysafer
transplantation when the patient’s condition has stabilised.
Although a trend to increased PGF has been reported in
patients who are bridged to transplantation with long-
term implanted VADs [5], post-transplant survival of these
patients does not appear to be compromised [15, 39].
Risk factors do not act in isolation, and it is likely that
the interaction between donor, recipient, and procedural
factors is a major determinant of the risk of PGF. A clear
example of this is the interaction between donor age and
ischaemic time reported by Russo et al. [16]. In that study,
there was no detectable adverse eﬀect of ischaemic time
on survival after heart transplantation when the donor was
less than 20 years of age. In contrast, when the donor age
increased above 20 years, a prolonged ischaemic time had
a signiﬁcant negative impact on survival [17]. This eﬀect
became even more marked when the donor age exceeded 35
years. The association of increasing donor age with PGF is
likely related to the decreased ability of the aging heart to
tolerate ischaemic insults as well as the increased incidence
of intrinsic cardiac pathology with age [20].
5.1. PGF Predictive Tool. Given that multiple factors in
the donor, the transplantation process and the recipient
contributetotheriskofPGF,thedevelopmentofapredictive
tool, and scoring system that combines known risk factors
has been reported [9, 40]. Suggested variables have included
donorandrecipientage,donorinotropicdependence,recipi-
entrightatrialpressure,andischaemictime[9].Withfurther
understanding of the aetiology of PGF, as well as identiﬁca-
tion and conﬁrmation of risk factors, an accurate predictive
scoring tool is imminent in the near future. The utility of any
predictive tool remains to be determined, but it does serve to
emphasise the importance of careful donor-recipient match-
ing in the prevention of this life-threatening complication.
6. Management
The treatment of PGF remains extremely challenging—a
substantial 30-day mortality rate is seen despite intensive
p h a r m a c o l o g i c a la sw e l la sm e c h a n i c a lc i r c u l a t o r ys u p p o r t
(IABP, ECMO, VAD) used in this critical period [1, 2].
In milder cases of primary allograft dysfunction, high-dose
inotropic agents may be suﬃcient to restore myocardial con-
tractility and haemodynamic stability. A variety of inotropic
agents have been used to treat PGF include catecholamines,
phosphodiesterase inhibitors, and more recently levosimen-
dan [41–43].
With more severe cases of graft failure, mechanical
circulatory support with intra-aortic counterpulsation or
VA extracorporeal mechanical support (ECMO) may be
needed to maintain haemodynamic support and perfusion
of vital organs. In our institution, the decision to institute
ECMO has been made early, that is, in the operating room
when there has been diﬃculty with separating from car-
diopulmonary bypass despite a trial of inotropic/vasopressor
support [11]. We believe that early institution of ECMO
not only allows the heart more time to recover from the
multiple stresses to which it has been exposed but also
prevents development of multisystem organ failure which
would otherwise occur if there is a period of uncorrected
cardiogenic shock. Recent advances in ECMO circuit design
have resulted in a signiﬁcantly improved survival rates and
fewer complications compared with practice not longer than
a decade ago, when paracorporeal ventricular assist devices
were used for left ventricular support and centrifugal pumps
for right ventricle support [7, 11, 44, 45].
Heart transplant recipients with PGF remain supported
on ECMO until graft function improves. In our experience,Journal of Transplantation 5
Table 3: Pharmacological activation of prosurvival kinases in a model of donor heart preservation.
Agent (s)1 Storage
time (h)
Poststorage
CO recov2
Prosurvival kinase phosphorylation3
Other salient ﬁndings Ref.
Akt ERK STAT3
GTN (0.1mg/mL) 6 2.5 0 + nd4 ↓ cleaved Casp 3 [61]
Carip (10μM) 6 3.5 0 ++ nd4 ↓ cleaved Casp 3 [61]
INO 1153 (1μM) 6 2.5 +++ + nd4 Recovery of function
abolished by Akt inhib [62]
Zonip (1μM) 6 14 0 +++ +++
Zonip abolished LDH
release; ↓ cleaved Casp
3;
Inhib of STAT3 phos
abolished recovery of
f’n.
[63]
N e ur eg(1 4nM) 6 1 3 ++ +++ +++ Recovery of function
abolished by Akt inhib [64]
EPO (5units/mL) 6 16 0 0 +++
Inhib of STAT3 phos
abolished recovery of
f’n.
[65]
Neureg + GTN +
Carip 10 13 ++ 0 +
Triple supplement ↓
contraction band
necrosis
[64]
1Agent(s) added to Celsior arresting and storage solution. Abbreviations/drug classes are as follows: GTN—glyceryl trinitrate (nitric oxide donor); Carip—
cariporide, Zonip—zoniporide, (both sodium/hydrogen exchange inhibitors); INO 1153—poly(ADPribose) polymerase inhibitor; Neureg—recombinant
human Neuregulin-1 peptide; EPO—erythropoietin. 2Recovery of cardiac output expressed as fold increase over Celsior-stored hearts (P ≤ 0.05); 3increase
in survival kinase phosphorylation over Celsior-stored hearts; +++: intense; ++: moderate; +: weak; 4nd-not determined;
this has generally been within 72 hours; however, heart
recovery has been observed as early as 1 day and as late
as 7 days after transplant [11]. Assessment of the timing
of cardiac recovery is usually judged by daily bedside
echocardiographywithbriefreductioninECMOﬂowduring
echocardiographicexamination.Themajorityofthepatients
in our series have had peripheral femoral venous and arterial
cannulas placed for ECMO support, and in most cases, it has
been possible to remove these cannulae in the intensive care
unit without the need to return to the operating theatre.
In cases with pre-existing recipient pulmonary hyper-
tension, PGF is usually manifested as right ventricular dys-
functionintheimmediatepost-transplantperiod.Treatment
includes administration of speciﬁc pulmonary vasodilators
such as inhaled nitric oxide to lower pulmonary vascular
resistance [46] however, mechanical circulatory support
may be needed [45]. Long-term administration of selec-
tive pulmonary vasodilators (prostacyclin, sildenaﬁl) or in
some cases implantation of left ventricular assist devices in
potential heart transplant recipient with ﬁxed pulmonary
hypertension has been reported to produce sustained low-
ering of pulmonary vascular resistance allowing orthotopic
heart transplantation to be performed without any increase
in perioperative graft failure or mortality [47, 48].
7.Prognosis
PGF is the leading cause of death in the ﬁrst month after
heart transplantation. Although registry studies indicate that
the number of early deaths due to PGF has not changed
over the last two decades [1, 2], this is in the setting of
an increasing incidence of PGF reported in the literature
[3, 4, 11, 14]. This suggests that the prognosis for patients
diagnosed with PGF is improving, most likely as a result
of the improved eﬃcacy and safety of pharmacological and
ECMO support in these critically ill patients [3, 11, 14]. In
our own experience of 17 patients supported on ECMO for
PGF, one month survival was 82% [11].
The impact of PGF beyond the ﬁrst month after trans-
plantation is less clear, but also likely to be signiﬁcant. Severe
ischaemia-reperfusioninjuryhasbeenshownexperimentally
to upregulate multiple proinﬂammatory mediators which
may prime the graft for acute rejection [25, 26] and also
predispose the graft to allograft vasculopathy [49], both of
which could contribute to graft failure at later time points.
8. Prevention and Areas for Future
Improvement
Given the cumulative impact of the multiple risk factors
that contribute to the development of PGF, careful matching
between donor and recipient is critical to minimising the
risk of PGF. Unfortunately, the logistics of transplantation
sometimes dictate that unfavourable risk factor interactions
cannot be avoided. While some risk factors (e.g., donor
and recipient age) are not modiﬁable, other risk factors
(e.g., donor heart ischaemia-reperfusion injury sustained
following brain death or during organ procurement and
preservation) may be amenable to therapeutic intervention.
The period between brain death and heart retrieval
is one in which heart function can deteriorate rapidly.
Optimal management of the brain dead donor during this6 Journal of Transplantation
period remains a contentious issue. More than 90% of brain
dead donors receive one or more inotropic or vasopressor
infusions most commonly noradrenaline [50]. While low-
dose infusions of catecholamines appear to be safe, high-
dose infusions increase the risk of PGF and should be
avoided [3, 6, 34]. There has been a longstanding interest
in the administration of pituitary-dependent hormones
in the optimisation of donor organ quality after brain
death. Vasopressin is an eﬀective alternative to noradrenaline
for maintaining blood pressure, and its use may prevent
the need for escalating doses of noradrenaline [51, 52].
On the other hand, the value of thyroid hormone and
corticosteroids in this setting is still controversial. While
large-scale retrospective analyses support a role for these
drugs [53, 54], prospective randomised controlled trials to
date have failed to demonstrate any improvement in cardiac
function or outcome after transplantation [55, 56].
The period of heart storage and transport is the second
period that oﬀers an opportunity to intervene. Currently
most hearts are stored and transported in cold cardio-
plegic/preservation solutions. The many commercial and in-
house cardioplegic/preservation solutions in routine clinical
use not only emphasise the complexity of the molecular and
cellular mechanisms that underlie ischaemia-reperfusion
injurybutalsothelackofconsensusastotheoptimalstrategy
for organ preservation [57]. Cardioplegic/storage solutions
such as St Thomas’ Solution No. 2 (Plegisol), Bretschneider
(Custodiol), and Celsior, have been in widespread clinical
use since the early 1990’s [58–60] and appear to provide
adequate protection of “standard criteria” of donor hearts
subjected to ischaemic times of less than 4 hours [1]. The
cardioprotective capacities of such formulations may be
suboptimal for the increasing numbers of “marginal” donor
hearts seen in current clinical practice, particularly those
subjected to prolonged ischaemic times.
Elucidation of the mechanisms of ischaemia-reperfusion
injury over this same period of time has suggested novel
strategies to enhance the cardioprotective capacities of
existing preservation solutions. The search for an over-
arching protective strategy against cardiac reperfusion injury
has been advanced by the realisation that ischemic pre- and
postconditioning as well as a number of pharmacological
agents that mimic these physiological strategies can activate
prosurvival signalling pathways such as PI3K/Akt, ERK
1/2 and STAT3 at reperfusion (for review see Hausenloy
et al., [66]). Consistent with this mechanism, we have
recently demonstrated that rat hearts arrested and stored
for 6 or 10 hours in Celsior solution supplemented with
the conditioning agents glyceryl trinitrate (GTN), a nitric
oxide donor, and cariporide, a sodium hydrogen exchange
inhibitorsigniﬁcantlyimprovedpoststoragecardiacfunction
that could be abolished by inhibition of the mitochondrial
KATP channel, a key target of prosurvival signalling pathways
[67]. These ﬁndings have recently been further veriﬁed in
a translational porcine orthotopic heart transplant model
incorporatingdonorbraindeath.Here,donorheartsarrested
6 hours after brain death and stored in Celsior supplemented
with GTN and cariporide could be successfully weaned from
cardiopulmonary bypass after 14-hour hypothermic storage
[68]. In addition, we have demonstrated that appropriate
pharmacological supplementation of the arresting and stor-
age solution can activate survival signalling after reperfusion
in a model of a normal donor heart exposed to storage
times that would class them as “marginal” (6hr storage) or
unsuitable for transplant (10 hour storage) (Table 3).
An alternative to cold static storage is ex vivo perfusion.
There is limited experience with this approach in heart
transplantation [69]; however, a recent large randomised
controlled trial in deceased kidney transplantation revealed
a signiﬁcant reduction in primary graft dysfunction and
improved graft survival at one year after transplant in
machine-preserved kidneys [70]. These beneﬁts were par-
ticularly marked in kidneys obtained from marginal donors
[71].
In summary, the increasing reliance on “marginal”
donors to meet the ever-increasing demand for heart trans-
plantation means that PGF is likely to remain a frequent
complication.Althoughtherehavebeensigniﬁcantimprove-
ments in the treatment of established PGF, it still carries a
high morbidity and mortality. While it is possible that some
casesofPGFmaybepreventedbycarefulmatchingofdonors
and recipients, complete prevention of PGF will require
the development of more eﬀective donor management and
donor heart preservation strategies. These remain high-
priority areas for ongoing basic and clinical research.
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